Loading...
•
Sep 30, 2020
Adaptive Biotechnologies Q3 2020 Earnings Report
Adaptive Biotechnologies reported financial results, demonstrating the unique capability of their platform and the key role of the immune response.
Key Takeaways
Adaptive Biotechnologies reported a revenue of $26.3 million for Q3 2020, a 1% increase compared to Q3 2019. The company's net loss was $36.7 million, and operating expenses totaled $63.3 million.
Revenue was $26.3 million, representing a 1% increase from the third quarter in the prior year.
Clinical sequencing volume increased 58% compared to the third quarter 2019.
Identified two antibodies against SARS-CoV-2 that neutralize the virus at very low concentrations.
Top-line results from a second real-world study demonstrated T-cell testing outperforms serology in identifying past SARS-CoV-2 infections.
Forward Guidance
Adaptive Biotechnologies is not providing 2020 financial guidance due to the continued uncertainties from the impact of COVID-19.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...